Full Press Release Details
SHAREHOLDER UPDATE: CREATIVE MEDICAL TECHNOLOGY
Phoenix, AZ 8-14-18, (OTCQB-CELZ) Creative Medical Technology
Holdings, Inc. announced today an update of its corporate activities.
Debt: Since our last 8k on debt reduction an additional
$268,858.00 has been extinguished.
CaverStem : Domestic recruitment, vetting
and training of physicians on the CaverStem program for the use of the patients own stem cells for the treatment of
erectile dysfunction is continuing post AUA Conference in May 2018.
We wish to welcome some of the physicians in the CaverStem program;
Elias Said MD and Mark Bieri MD located in Las Cruces, NM. (caverstem-nm.com)
Victor Liu MD located in San Francisco, CA, (caverstem-sanfrancisco.com)
David Brown MD located in San Diego, CA, (caverstem-sandiego.com)
Barton Wachs MD located in Orange County, CA, (caverstem-oc.com)
Sheldon Freedman MD located in Las Vegas, CA, (caverstem-lasvegas.com)
Perinchery Narayan MD at North Florida Urology with offices
in Orlando, Ocala, Gainsville, St. Augustine and Palatka, Fl. (caverstem-northflorida.com)
CaverStem International:
Implementation of our contract with Promo Med continues to move
forward. We are also currently working with Dr. Alexander Buchmann with Alto Uro in Bern Switzerland to establish the CaverStem
program in Switzerland, Germany and Austria. We are pleased with the opportunity to work with a highly regarded physician such
as Dr. Buchmann to expand CaverStem in Europe.
CaverStem Clincal Trial: As per our contract
with LA BioMed, the results will be made available 12 months after the last patient was enrolled. This will occur the end of August
2018. Once the data is received, analyzed and peer reviewed, the results will be jointly released by our company and LA BioMed.
American Urological Association Regional Conference: We
will be exhibiting at this conference in Chicago September 5-9, 2018.
StemSpine : This patented technology for
the use of stem cells for the treatment of degenerative disc disease represents the entry into a multi billion dollar market. The
StemSpine model is the use of stem cells from bone marrow from the as with the CaverStem program.
AmnioStem : The AmnioStem program
is meeting our expected development milestones.
Stroke, Medical Wasting, Radiation Toxicity and other patents: Our intellectual property portfolio is meeting our expected milestones and we intend to release information as our progress
Summary: We have faced challenges but we continue to
grow our programs strategically and efficiently. We are optimistic with the progress and fundamentals of our company.
We wish to thank our shareholders for their continued support.
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a commercial stage
biotechnology company currently trading on the OTCQB under the ticker symbol CELZ. For further information about the company go
to www.creativemedicaltechnology.com. For more information on our Caverstem procedure please go to www.caverstem.com.
Forward-Looking Statements
OTC Markets has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited
to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc.
Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual
results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by
Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website
Chief Executive Officer